Allergy Serum: The Misnomer Patients Need to Understand

No. Despite the colloquial term "allergy serum," there is no blood, plasma, or blood-derived product in a standard allergy shot. The vial contains allergenic extract — proteins and glycoproteins from natural source materials such as pollens, dust mites, and animal danders — suspended in a diluent such as 50% glycerin or normal saline and preserved with 0.4% phenol. The FDA Center for Biologics Evaluation and Research defines injectable allergen extracts as "sterile liquids manufactured from natural substances," not blood-derived products. The exception is that human serum albumin (HSA) at trace concentrations (~0.03%) is used in some very dilute diluent formulations, but this is an FDA-licensed stabilizer, not a blood product in the clinical sense.

The term "allergy serum" is a historical holdover from the early twentieth century when "serum" was used loosely to describe any liquid therapeutic preparation. In modern medicine, serum refers specifically to blood minus clotting factors. The 1998 WHO position paper on allergen immunotherapy (Bousquet, Lockey, Malling, JACI 1998) acknowledged the confusion and proposed "allergen vaccine" as a more accurate term, since the preparation works as an immune modifier. US specialty practice today predominantly uses "allergen immunotherapy" or "allergen extract." When patients use the word "serum," they typically mean the allergen extract or the vial set — which is accurate in colloquial usage but not in strict medical terminology.

An allergy shot vial contains four ingredient categories per FDA CBER and Cox 2011 PP3. First, the active ingredient: allergen extract — proteins and glycoproteins from FDA-licensed natural source materials matching the patient's IgE sensitization profile. Second, the diluent: most commonly 50% glycerin, sometimes 0.9% normal saline. Third, the preservative: 0.4% phenol is standard; thimerosal is largely phased out. Fourth, buffer salts where present for pH stability. The specific allergen composition is patient-specific — prepared from FDA-licensed concentrate stocks of manufacturers such as Stallergenes Greer, ALK-Abelló, or Jubilant HollisterStier based on the allergens identified in the patient's IgE workup.

Per FDA CBER, the 19 standardized allergenic extracts are: short ragweed (potency by Amb a 1 content), cat hair and cat pelt (potency by Fel d 1), eight grass pollens (Bermuda, Kentucky/June Bluegrass, Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, Timothy), two house dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), and five Hymenoptera venoms (honey bee, yellow jacket, yellow hornet, white-faced hornet, and wasp/mixed vespid). Standardized extracts have FDA-assigned national reference standards ensuring lot-to-lot and manufacturer-to-manufacturer potency consistency. Everything else — most tree pollens, weeds beyond ragweed, dog, horse, molds — is non-standardized and labeled by weight/volume or PNU.

Glycerin (50%) serves as the primary diluent and stabilizer in most US allergen extract preparations. It performs two functions: it is bacteriostatic at concentrations above 20%, inhibiting microbial growth without requiring high phenol concentrations, and it stabilizes the allergen proteins against degradation during storage. Per the AAAAI extract-preparation manual, dilutions must be bacteriostatic — either phenol at ≥0.25% or glycerin at ≥20%. High-glycerin formulations also help protect against the degradation of labile pollen allergens when high-protease extracts (molds, dust mites) are mixed in multi-allergen vials, though proteolytic extracts are typically separated into their own vials per AAAAI mixing guidance.

Thimerosal — the mercury-containing preservative used in older allergy extract formulations — has been largely phased out of US allergen immunotherapy practice per current ACAAI/AAAAI guidance. Modern US extract preparations predominantly use phenol (0.4%) and glycerin-based bacteriostatic systems instead. However, "largely phased out" means some specific products may still contain trace amounts. Patients with concerns about thimerosal should request the package insert from their allergist for the specific FDA-licensed extract products being used in their formulation. The package insert, required for all FDA-licensed allergen extracts, lists every ingredient by name and concentration.

The allergen composition of a patient's vial is determined entirely by specific IgE testing — either skin prick testing or serum-specific IgE blood testing (ImmunoCAP or similar). Only allergens confirmed to be driving the patient's IgE-mediated reactions are included in the formulation. Including allergens the patient is not sensitized to adds no benefit and may dilute the effective dose of relevant allergens in multi-allergen vials. Per Cox 2011 PP3, the allergist reviews the IgE sensitization profile alongside clinical history before designing the extract formulation. This is why two patients presenting with similar symptoms may have completely different vial compositions — the formulation is driven by individual IgE biology, not by symptom phenotype alone.